对2型糖尿病和发生的外周动脉疾病的综合风险因素控制
Xiaohui Yu1, Zhan Lian2, Jinyi Wu3
1Department of Vascular Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
European journal of preventive cardiology
|October 31, 2025
概括
在2型糖尿病 (T2D) 中,优化饮食和血压等风险因素显著降低了周围动脉疾病 (PAD) 的风险. 综合管理消除了T2D患者与没有糖尿病患者相比,PAD风险过多.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 患有2型糖尿病 (T2D) 的患者面临的外周动脉疾病 (PAD) 的风险比一般人群更高.
- 了解减轻这种增加风险的因素对于患者的治疗结果至关重要.
研究的目的:
- 调查控制多种风险因素是否可以降低与T2D相关的PAD风险.
- 量化控制风险因素数量与T2D患者PAD发病率之间的关联.
主要方法:
- 一项队列研究涉及14458名T2D患者和56961名来自英国生物库的匹配对照.
- 根据可控风险因素的数量对T2D参与者进行了分层:吸烟,体力活动,饮食,HbA1c,BMI,血压,LDL-C和尿蛋白.
主要成果:
- 在11.9年内,PAD发病率在T2D患者中为2.8%,在对照组中为1.2%.
- 在T2D患者中,每个额外控制的风险因素都将PAD风险降低约23%.
- 与非T2D患者相比,具有≥6个可控风险因素的T2D患者的PAD危险比率为0.82 (95% CI 0.511.31),表明没有过度风险.
结论:
- 多种风险因素的最佳控制可以消除T2D患者过度PAD风险.
- 促进综合性风险因素管理对于降低T2D患者中PAD负担至关重要.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
232
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
232
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Coronary Artery Disease I: Introduction
868
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
868
Diabetes: Management and Pharmacotherapy
856
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
856
Peripheral Artery Disease I: Introduction
301
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
301
Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311


